AU2004207272A1 - TKTS as modifiers of the beta-catenin pathway and methods of use - Google Patents

Description

WO 2004/067721 PCT/US2004/002321 TKTS AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE REFERENCE TO RELATED APPLICATIONS 5 This application claims priority to U.S. provisional patent application 60/443,478 filed 1/29/2003. The content of the prior application are hereby incorporated in their entirety. BACKGROUND OF THE INVENTION 10 The Drosophila Melanogaster Armadillo/beta-catenin protein is implicated in multiple cellular functions. The protein functions in cell signaling via the Wingless (Wg)/Wnt signaling pathway. It also functions as a cell adhesion protein at the cell membrane in a complex with E-cadherin and alpha-catenin (Cox et al. (1996) J. Cell Biol. 134: 133-148; Godt and Tepass (1998) Nature 395: 387-391; White et al. (1998) J Cell 15 biol. 140:183-195). These two roles of beta -catenin can be separated from each other (Orsulic and Peifer (1996) J. Cell Biol. 134: 1283-1300; Sanson et al. (1996) Nature 383: 627-630). In Wingless cell signaling, beta -catenin levels are tightly regulated by a complex containing APC, Axin, and GSK3 beta /SGG/ZW3 (Peifer et al. (1994) Development 120: 20 369-380). The Wingless/ beta -catenin signaling pathway is frequently mutated in human cancers, particularly those of the colon. Mutations in the tumor suppressor gene APC, as well as point mutations in beta -catenin itself lead to the stabilization of the beta -catenin protein and inappropriate activation of this pathway. 25 Transketolase (TKT)is a thiamine-dependent enzyme that links the pentose phosphate pathway with the glycolytic pathway (Abedinia, M. et al (1992) Biochem. Biophys. Res. Commun. 183: 1159-1166). The pentose phosphate pathway, which is active in most tissues, provides sugar phosphates for intermediary biosynthesis, especially nucleotide metabolism, and generates the biosynthetic reducing power for the cell in the 30 form of NADPH. Transketolase is directly involved in the branch of the pathway that channels excess sugar phosphates to glycolysis, enabling the production of NADPH to be maintained under different metabolic conditions. NADPH is critical for maintaining cerebral glutathione, and thus it is likely that transketolase plays an important role in brain metabolism. A variant transketolase enzyme, TKTL1, may be responsible for the genetic WO 2004/067721 PCT/US2004/002321 predisposition to the development of Wernicke-Korsakoff syndrome (Coy JF et al (1996) Genomics 32: 309-316). The ability to manipulate the genomes of model organisms such as Drosophila provides a powerful means to analyze biochemical processes that, due to significant 5 evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the 10 correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33 74; Watson KL., et al., 1994 J Cell Sci. 18: 19-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; and Booth DR. 1999 Cancer Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried 15 out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the 20 genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as beta-catenin, modifier genes can be identified that may be attractive candidate targets for novel therapeutics. All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in 25 their entireties. SUMMARY OF THE INVENTION We have discovered genes that modify the beta-catenin pathway in Drosophila, and identified their human orthologs, hereinafter referred to as transketolase (TKT). The 30 invention provides methods for utilizing these beta-catenin modifier genes and polypeptides to identify TKT-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired beta catenin function and/or TKT function. Preferred TKT-modulating agents specifically bind to TKT polypeptides and restore beta-catenin function. Other preferred TKT-modulating 2 WO 2004/067721 PCT/US2004/002321 agents are nucleic acid modulators such as antisense oligomers and RNAi that repress TKT gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA). TKT modulating agents may be evaluated by any convenient in vitro or in vivo 5 assay for molecular interaction with a TKT polypeptide or nucleic acid. In one embodiment, candidate TKT modulating agents are tested with an assay system comprising a TKT polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate beta-catenin modulating agents. The assay system may be cell-based or cell-free. TKT-modulating 10 agents include TKT related proteins (e.g. dominant negative mutants, and biotherapeutics); TKT -specific antibodies; TKT -specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with TKT or compete with TKT binding partner (e.g. by binding to a TKT binding partner). In one specific embodiment, a small molecule modulator is identified using a transferase assay. In 15 specific embodiments, the screening assay system is selected from a binding assay, an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay. In another embodiment, candidate beta-catenin pathway modulating agents are further tested using a second assay system that detects changes in the beta-catenin 20 pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the beta-catenin pathway, such as 25 an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer). The invention further provides methods for modulating the TKT function and/or the beta-catenin pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a TKT polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to 30 a mammalian animal predetermined to have a pathology associated with the beta-catenin pathway. 3 WO 2004/067721 PCT/US2004/002321 DETAILED DESCRIPTION OF THE INVENTION In a screen to identify enhancers and suppressors of the Wg signaling pathway, we generated activated beta -catenin models in Drosophila based on human tumor data (Polakis (2000) Genes and Development 14: 1837-1851). We identified modifiers of the 5 Wg pathway and identified their orthologs. The CG8036 gene was identified as a modifier of the beta-catenin pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, TKT genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective beta catenin signaling pathway, such as cancer. 10 In vitro and in vivo methods of assessing TKT function are provided herein. Modulation of the TKT or their respective binding partners is useful for understanding the association of the beta-catenin pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for beta-catenin related pathologies. TKT-modulating agents that act by inhibiting or enhancing TKT expression, 15 directly or indirectly, for example, by affecting a TKT function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. TKT modulating agents are useful in diagnosis, therapy and pharmaceutical development. Nucleic acids and polypeptides of the invention 20 Sequences related to TKT nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) number) as GI#s 4507520 (SEQ ID NO:1), 1297296 (SEQ ID NO:2), 37266 (SEQ ID NO:3), 388890 (SEQ ID NO:4), 7110726 (SEQ ID NO:5), 19263484 (SEQ ID NO:6), 14149796 (SEQ ID NO:7), and 20379576 (SEQ ID NO:8) for nucleic acid, and GI#s 4507521 (SEQ ID 25 NO:9), 7110727 (SEQ ID NO:10), and 14149797 (SEQ ID NO:11) for polypeptides. The term "TKT polypeptide" refers to a full-length TKT protein or a functionally active fragment or derivative thereof. A "functionally active" TKT fragment or derivative exhibits one or more functional activities associated with a full-length, wild-type TKT protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind 30 natural cellular substrates, etc. The functional activity of TKT proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan et al., eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. In one embodiment, a functionally active TKT polypeptide is a TKT derivative capable of rescuing defective endogenous 4 WO 2004/067721 PCT/US2004/002321 TKT activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of a TKT, such as a binding domain. Protein domains can be identified using the PFAM program (Bateman 5 A., et al., Nucleic Acids Res, 1999, 27:260-2). For example, the transketolase domain (PFAM 00456) of TKT from GI#s 4506521, 7110727, and14149797 (SEQ ID NOs:9, 10, and 11, respectively) is located at approximately amino acid residues 14-304, 1-222, and 15-308, respectively. Methods for obtaining TKT polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain 10 containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of a TKT. In further preferred embodiments, the fragment comprises the entire functionally active domain. The term "TKT nucleic acid" refers to a DNA or RNA molecule that encodes a 15 TKT polypeptide. Preferably, the TKT polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human TKT. Methods of identifying orthlogs are known in the art. Normally, orthologs in different species retain 20 the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad 25 Sci (1998) 95:5849-5856; Huynen MA et al., Genome Research (2000) 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD et al, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse species (e.g., retrieved through 30 BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species, such as Drosophila, 5 WO 2004/067721 PCT/US2004/002321 may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term "orthologs" encompasses paralogs. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative 5 sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU BLAST-2.0a19 (Altschul et al., J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values 10 and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the 15 same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation. A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the 20 protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and 25 interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine. Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, Advances in Applied Mathematics 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, J. of Molec.Biol., 147:195-197; Nicholas et al., 1998, "A Tutorial on 30 Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, Genomics 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: Atlas of Protein Sequences and Structure, M. 0. Dayhoff ed., 5 suppl. 3:353 358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized 6 WO 2004/067721 PCT/US2004/002321 by Gribskov (Gribskov 1986 Nucl. Acids Res. 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity." 5 Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of a TKT. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (e.g., Current Protocol in 10 Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of a TKT under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to 15 overnight at 650 C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 pg/ml herring sperm DNA; hybridization for 18-20 hours at 650 C in a solution containing 6X SSC, IX Denhardt's solution, 100 pg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65* C for 1h in a solution 20 containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate). In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40' C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 pg/ml denatured salmon sperm DNA; hybridization for 18-20h 25 at 40 C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCI (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 pg/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 550 C in a solution containing 2X SSC and 0.1% SDS. Alternatively, low stringency conditions can be used that are: incubation for 8 30 hours to overnight at 370 C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 pg/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 370 C for 1 hour. 7 WO 2004/067721 PCT/US2004/002321 Isolation, Production, Expression, and Mis-expression of TKT Nucleic Acids and Polypeptides TKT nucleic acids and polypeptides are useful for identifying and testing agents that modulate TKT function and for other applications related to the involvement of TKT 5 in the beta-catenin pathway. TKT nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. 10 For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of proteins to be purified for screening or antibody production may require the addition of specific tags (e.g., generation of fusion proteins). Overexpression 15 of a TKT protein for assays used to assess TKT function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (e.g., Higgins SJ and Hames BD (eds.) Protein Expression: A Practical Approach, Oxford University 20 Press Inc., New York 1999; Stanbury PF et al., Principles of Fermentation Technology, 2 "d edition, Elsevier Science, New York, 1995; Doonan S (ed.) Protein Purification Protocols, Humana Press, New Jersey, 1996; Coligan JE et al, Current Protocols in Protein Science (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant TKT is expressed in a cell line known to have defective beta-catenin function. The 25 recombinant cells are used in cell-based screening assay systems of the invention, as described further below. The nucleotide sequence encoding a TKT polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native TKT gene and/or its 30 flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g. baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with 8 WO 2004/067721 PCT/US2004/002321 bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used. To detect expression of the TKT gene product, the expression vector can comprise a promoter operably linked to a TKT gene nucleic acid, one or more origins of replication, 5 and, one or more selectable markers (e.g. thymidine kinase activity, resistance to antibiotics, etc.). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the TKT gene product based on the physical or functional properties of the TKT protein in in vitro assay systems (e.g. immunoassays). The TKT protein, fragment, or derivative may be optionally expressed as a fusion, 10 or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, 15 e.g. by use of a peptide synthesizer (Hunkapiller et al., Nature (1984) 310:105-111). Once a recombinant cell that expresses the TKT gene sequence is identified, the gene product can be isolated and purified using standard methods (e.g. ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native TKT proteins can be purified from natural sources, 20 by standard methods (e.g. immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography. The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of TKT or other genes associated with the beta-catenin 25 pathway. As used herein, mis-expression encompasses ectopic expression, over expression, under-expression, and non-expression (e.g. by gene knock-out or blocking expression that would otherwise normally occur). Genetically modified animals 30 Animal models that have been genetically modified to alter TKT expression may be used in in vivo assays to test for activity of a candidate beta-catenin modulating agent, or to further assess the role of TKT in a beta-catenin pathway process such as apoptosis or cell proliferation. Preferably, the altered TKT expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or 9 WO 2004/067721 PCT/US2004/002321 apoptosis compared to control animals having normal TKT expression. The genetically modified animal may additionally have altered beta-catenin expression (e.g. beta-catenin knockout). Preferred genetically modified animals are mammals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include 5 zebrafish, C. elegans, and Drosophila. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous 10 nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal. Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., 15 and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford et al.; for transgenic Drosophila see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. et al., A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic 20 Zebrafish see Lin S., Transgenic Zebrafish, Methods Mol Biol. (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for transgenic rats see Hammer et al., Cell (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods 25 such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. et al. (1997) Nature 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669). 30 In one embodiment, the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous TKT gene that results in a decrease of TKT function, preferably such that TKT expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked 10 WO 2004/067721 PCT/US2004/002321 out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse TKT gene is used to construct a 5 homologous recombination vector suitable for altering an endogenous TKT gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, Science (1989) 244:1288-1292; Joyner et al., Nature (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, supra; Pursel et al., Science (1989) 10 244:1281-1288; Simms et al., Bio/Technology (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MI et al., (1994) Scan J Immunol 40:257-264; Declerck PJ et al., (1995) J Biol Chem. 270:8397-400). 15 In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the TKT gene, e.g., by introduction of additional copies of TKT, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the TKT gene. Such regulatory sequences include 20 inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock in can be homozygous or heterozygous. Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso et al., 25 PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other 30 containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the 11 WO 2004/067721 PCT/US2004/002321 transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) Nat Genet 25:83-6). The genetically modified animals can be used in genetic studies to further elucidate the beta-catenin pathway, as animal models of disease and disorders implicating defective 5 beta-catenin function, and for in vivo testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered TKT function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered TKT expression that receive 10 candidate therapeutic agent. In addition to the above-described genetically modified animals having altered TKT function, animal models having defective beta-catenin function (and otherwise normal TKT function), can be used in the methods of the present invention. For example, a beta-catenin knockout mouse can be used to assess, in vivo, the activity of a candidate 15 beta-catenin modulating agent identified in one of the in vitro assays described below. Preferably, the candidate beta-catenin modulating agent when administered to a model system with cells defective in beta-catenin function, produces a detectable phenotypic change in the model system indicating that the beta-catenin function is restored, i.e., the cells exhibit normal cell cycle progression. 20 Modulating Agents The invention provides methods to identify agents that interact with and/or modulate the function of TKT and/or the beta-catenin pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety 25 of diagnostic and therapeutic applications associated with the beta-catenin pathway, as well as in further analysis of the TKT protein and its contribution to the beta-catenin pathway. Accordingly, the invention also provides methods for modulating the beta catenin pathway comprising the step of specifically modulating TKT activity by administering a TKT-interacting or -modulating agent. 30 As used herein, an "TKT-modulating agent" is any agent that modulates TKT function, for example, an agent that interacts with TKT to inhibit or enhance TKT activity or otherwise affect normal TKT function. TKT function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra cellular activity. In a preferred embodiment, the TKT - modulating agent specifically 12 WO 2004/067721 PCT/US2004/002321 modulates the function of the TKT. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the TKT polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the TKT. These phrases also encompass modulating agents that alter 5 the interaction of the TKT with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of a TKT, or to a protein/binding partner complex, and altering TKT function). In a further preferred embodiment, the TKT- modulating agent is a modulator of the beta-catenin pathway (e.g. it restores and/or upregulates beta-catenin function) and thus is also a beta-catenin-modulating agent. 10 Preferred TKT-modulating agents include small molecule compounds; TKT interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or 15 excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19 th edition. Small molecule modulators 20 Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight up to 10,000, preferably up to 5,000, more preferably up to 1,000, and most preferably up to 500 daltons. This class of modulators 25 includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the TKT protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also 30 be identified by screening compound libraries for TKT-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948). Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be 13 WO 2004/067721 PCT/US2004/002321 designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the beta-catenin pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and 5 candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using in vitro and in vivo assays to optimize activity and minimize toxicity for pharmaceutical development. 10 Protein Modulators Specific TKT-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the beta-catenin pathway and related disorders, as well as in validation assays for other TKT-modulating agents. In a preferred embodiment, TKT-interacting proteins affect normal TKT function, including transcription, protein 15 expression, protein localization, and cellular or extra-cellular activity. In another embodiment, TKT-interacting proteins are useful in detecting and providing information about the function of TKT proteins, as is relevant to beta-catenin related disorders, such as cancer (e.g., for diagnostic means). A TKT-interacting protein may be endogenous, i.e. one that naturally interacts 20 genetically or biochemically with a TKT, such as a member of the TKT pathway that modulates TKT expression, localization, and/or activity. TKT-modulators include dominant negative forms of TKT-interacting proteins and of TKT proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous TKT-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: 25 A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature 30 (2000) 405:837-846; Yates JR 3P, Trends Genet (2000) 16:5-8). A TKT-interacting protein may be an exogenous protein, such as a TKT-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using 14 WO 2004/067721 PCT/US2004/002321 antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). TKT antibodies are further discussed below. In preferred embodiments, a TKT-interacting protein specifically binds a TKT protein. In alternative preferred embodiments, a TKT-modulating agent binds a TKT 5 substrate, binding partner, or cofactor. Antibodies In another embodiment, the protein modulator is a TKT specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in 10 screening assays to identify TKT modulators. The antibodies can also be used in dissecting the portions of the TKT pathway responsible for various cellular responses and in the general processing and maturation of the TKT. Antibodies that specifically bind TKT polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of TKT 15 polypeptide, and more preferably, to human TKT. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a FAb expression library, anti idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of TKT which are particularly antigenic can be selected, for example, by routine 20 screening of TKT polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Nati. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence of a TKT. Monoclonal antibodies with affinities of 108 M- preferably 109 M~ 1 to 1010 M- 1 , or stronger can be made by 25 standard procedures as described (Harlow and Lane, supra; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of TKT or substantially purified fragments thereof. If TKT fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous 30 amino acids of a TKT protein. In a particular embodiment, TKT-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, 15 WO 2004/067721 PCT/US2004/002321 which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols. The presence of TKT-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized 5 corresponding TKT polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used. Chimeric antibodies specific to TKT polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the 10 antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of 15 chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain -10% murine sequences and -90% human sequences, and thus further 20 reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370). TKT-specific single chain antibodies which are recombinant, single chain 25 polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546). Other suitable techniques for antibody production involve in vitro exposure of 30 lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, supra). 16 WO 2004/067721 PCT/US2004/002321 The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). 5 A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 10 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900). When used therapeutically in a patient, the antibodies of the subject invention are 15 typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg -to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in 20 association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical 25 stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about10 mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; W00073469). 30 Nucleic Acid Modulators Other preferred TKT-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit TKT activity. Preferred nucleic acid modulators interfere with the function of the TKT nucleic acid such as DNA replication, transcription, translocation of the TKT RNA to the site of 17 WO 2004/067721 PCT/US2004/002321 protein translation, translation of protein from the TKT RNA, splicing of the TKT RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the TKT RNA. In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently 5 complementary to a TKT mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. TKT-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The 10 oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents. 15 In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense 20 oligomers are well known in the art (e.g. see W099/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841). Alternative preferred TKT nucleic acid modulators are double-stranded RNA 25 species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in C. elegans, Drosophila, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 30 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Haniond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239 245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., 18 WO 2004/067721 PCT/US2004/002321 et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); W00129058; W09932619; Elbashir SM, et al., 2001 Nature 411:494-498). Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene 5 expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous 10 clinical trials to be safe and effective (Milligan JF, et al, Current Concepts in Antisense Drug Design, J Med Chem. (1993) 36:1923-1937; Tonkinson JL et al., Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65). Accordingly, in one aspect of the invention, a TKT-specific nucleic acid modulator is used in an assay to further elucidate the role of the TKT in the beta-catenin pathway, and/or its 15 relationship to other members of the pathway. In another aspect of the invention, a TKT specific antisense oligomer is used as a therapeutic agent for treatment of beta-catenin related disease states. Assay Systems 20 The invention provides assay systems and screening methods for identifying specific modulators of TKT activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the TKT 25 nucleic acid or protein. In general, secondary assays further assess the activity of a TKT modulating agent identified by a primary assay and may confirm that the modulating agent affects TKT in a manner relevant to the beta-catenin pathway. In some cases, TKT modulators will be directly tested in a secondary assay. In a preferred embodiment, the screening method comprises contacting a suitable 30 assay system comprising a TKT polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. tranferase activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates TKT 19 WO 2004/067721 PCT/US2004/002321 activity, and hence the beta-catenin pathway. The TKT polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above. Primary Assays 5 The type of modulator tested generally determines the type of primary assay. Primary assays for small molecule modulators For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that 10 recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS et al., Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially 15 purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (e.g., receptor-ligand binding), transcriptional activity (e.g., using a reporter gene), enzymatic activity (e.g., via a property of the substrate), activity of second messengers, immunogenicty and changes in cellular 20 morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected. Cell-based screening assays usually require systems for recombinant expression of 25 TKT and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of 30 protein complexes. In certain applications, when TKT-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the TKT protein may be assayed by various known methods such as substrate processing (e.g. ability of the candidate TKT-specific binding agents to function as negative effectors in TKT-expressing cells), binding equilibrium constants (usually at least 20 WO 2004/067721 PCT/US2004/002321 about 107 M-, preferably at least about 108 M-1, more preferably at least about 109 M-'), and immunogenicity (e.g. ability to elicit TKT specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing. 5 The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a TKT polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The TKT polypeptide can be full length or a fragment thereof that retains functional TKT activity. The TKT polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to 10 another tag. The TKT polypeptide is preferably human TKT, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the screening assay detects candidate agent-based modulation of TKT interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has TKT -specific binding activity, and can be used to assess normal TKT gene function. 15 Suitable assay formats that may be adapted to screen for TKT modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Sundberg SA, Curr Opin Biotechnol 2000, 11:47-53). In one preferred embodiment, screening assays uses 20 fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (e.g., Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, supra; 25 Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451). A variety of suitable assay systems may be used to identify candidate TKT and beta-catenin pathway modulators (e.g. U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); and U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described in more detail below. 30 Transketolases mediate transfer of aldehyde or ketone groups. Fluorimetric assays to assess transketolase activity have been described (Anderson SH and Nicol AD (1986) Ann Clin Biochem 23 (Pt 2):180-9). 21 WO 2004/067721 PCT/US2004/002321 Apoptosis assays. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin- 11 -dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis ( Lazebnik et al., 1994, Nature 371, 346), by following the incorporation of 5 fluorescein-dUTP (Yonehara et al., 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41). Other cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay. The caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell 10 death in many apoptotic pathways. In the caspase 3/7 assay (commercially available Apo ONET" Homogeneous Caspase-3/7 assay from Promega, cat# 67790), lysis buffer and caspase substrate are mixed and added to cells. The caspase substrate becomes fluorescent when cleaved by active caspase 3/7. The nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat# 15 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane 20 breaks down, allowing for accumalation in the cytoplasm. Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis. An apoptosis assay system may comprise a cell that expresses a TKT, and that optionally has defective beta catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild type cells). A test agent can be added to the apoptosis assay system and changes in 25 induction of apoptosis relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether TKT function plays a direct role in apoptosis. For example, an 30 apoptosis assay may be performed on cells that over- or under-express TKT relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the TKT plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437. 22 WO 2004/067721 PCT/US2004/002321 Cell proliferation and cell cycle assays. Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino et 5 al., 1986, Int. J. Cancer 38, 369; Campana et al., 1988, J. Immunol. Meth. 107, 79), or by other means. Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specfic to the phosphorylated form 10 of the serine 10 residue of histone H3. (Chadlee,D.N. 1995, J. Biol. Chem 270:20098 105). Cell Proliferation may also be examined using [ 3 H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [ 3 H]-thymidine into newly synthesized DNA. 15 Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL et al., 1998, In Vitro Cell Dev 20 Biol Anim 34:239-46). Yet another proliferation assay, the MTS assay, is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS. MTS assays are commercially available, for example, the Promega CellTiter 96* AQueous Non-Radioactive Cell Proliferation Assay (Cat.# G5421). Cell proliferation may also be assayed by colony formation in soft agar (Sambrook 25 et al., Molecular Cloning, Cold Spring Harbor (1989)). For example, cells transformed with TKT are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation. Cell proliferation may also be assayed by measuring ATP levels as indicator of metabolically active cells. Such assays are commercially available, for example Cell 30 Titer-GloTM, which is a luminescent homogeneous assay available from Promega. Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) Int J Radiat Biol Relat Stud Phys Chem Med 49:237-55). Cells transfected with a TKT may be stained with propidium iodide and evaluated in a flow 23 WO 2004/067721 PCT/US2004/002321 cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle. Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses a TKT, and that optionally has defective beta-catenin function (e.g. beta 5 catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is 10 initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test whether TKT function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express TKT relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the 15 TKT plays a direct role in cell proliferation or cell cycle. Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure 20 proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel@ (Becton Dickinson). Accordingly, an angiogenesis assay system may 25 comprise a cell that expresses a TKT, and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate beta catenin modulating agents. In some embodiments of the invention, the angiogenesis assay 30 may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether TKT function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express TKT relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the 24 WO 2004/067721 PCT/US2004/002321 TKT plays a direct role in angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among others, describe various angiogenesis assays. Hypoxic induction. The alpha subunit of the transcription factor, hypoxia 5 inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glyolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with TKT in hypoxic conditions (such as with 0.1% 02, 5% C02, and balance 10 N2, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman@. For example, a hypoxic induction assay system may comprise a cell that expresses a TKT, and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic 15 induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether TKT function plays a 20 direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express TKT relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the TKT plays a direct role in hypoxic induction. 25 Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The 30 wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2x final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a 25 WO 2004/067721 PCT/US2004/002321 membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader. Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or 5 recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate 10 reader. High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators 15 against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53). Tubulogenesis. Tubulogenesis assays monitor the ability of cultured cells, 20 generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix. Exemplary substrates include Matrigelm (Becton Dickinson), an extract of basement membrane proteins containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4'C and forms a solid gel at 37 C. Other suitable matrices comprise extracellular components 25 such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, Nature Medicine 5:1418-1423). These assays have traditionally involved 30 stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors. In a preferred embodiment, the assay is performed with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates. Moreover, we have found that different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory 26 WO 2004/067721 PCT/US2004/002321 angiogenic factors such as TNF-alpa. Thus, in a further preferred embodiment, a tubulogenesis assay system comprises testing a TKT's response to a variety of factors, such as FGF, VEGF, phorbol myristate acetate (PMA), TNF-alpha, ephrin, etc. 5 Cell Migration. An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, J Biol Chem 276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell 10 size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Coming Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but 15 longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS 20 FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As described above, a preferred assay system for migration/invasion assays comprises testing a TKT's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium. 25 Sprouting assay. A sprouting assay is a three-dimensional in vitro angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the 30 extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58). In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998). 27 WO 2004/067721 PCT/US2004/002321 Spheroids are harvested and seeded in 900pl of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100 pl of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37'C for 24h. Dishes are fixed at 5 the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid. Primary assays for antibody modulators 10 For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the TKT protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, supra). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting TKT-specific antibodies; others include FACS assays, radioimmunoassays, and 15 fluorescent assays. In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators. Primary assays for nucleic acid modulators 20 For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance TKT gene expression, preferably mRNA expression, In general, expression analysis comprises comparing TKT expression in like populations of cells (e.g., two pools of cells that endogenously or recombinantly express TKT) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA anid 25 protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (e.g., using the TaqMan@, PE Applied Biosystems), or microarray analysis may be used to confirm that TKT mRNA expression is reduced in cells treated with the nucleic acid modulator (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM et al., eds., John Wiley & Sons, Inc., chapter 4; 30 Freeman WM et al., Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2O1, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected witi specific antibodies or antisera directed against either the TKT protein or specific pepti -les. 28 WO 2004/067721 PCT/US2004/002321 A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, supra). In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve TKT mRNA expression, may also be used to test 5 nucleic acid modulators. Secondary Assays Secondary assays may be used to further assess the activity of TKT-modulating agent identified by any of the above methods to confirm that the modulating agent affects 10 TKT in a manner relevant to the beta-catenin pathway. As used herein, TKT-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with TKT. 15 Secondary assays generally compare like populations of cells or animals (e.g., two pools of cells or animals that endogenously or recombinantly express TKT) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate TKT-modulating agent results in changes in the beta-catenin pathway in comparison to untreated (or mock- or placebo-treated) cells or 20 animals. Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the beta-catenin or interacting pathways. Cell-based assays 25 Cell based assays may detect endogenous beta-catenin pathway activity or may rely on recombinant expression of beta-catenin pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means. 30 Animal Assays A variety of non-human animal models of normal or defective beta-catenin pathway may be used to test candidate TKT modulators. Models for defective beta catenin pathway typically use genetically modified animals that have been engineered to 29 WO 2004/067721 PCT/US2004/002321 mis-express (e.g., over-express or lack expression in) genes involved in the beta-catenin pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc. In a preferred embodiment, beta-catenin pathway activity is assessed by 5 monitoring neovascularization and angiogenesis. Animal models with defective and normal beta-catenin are used to test the candidate modulator's affect on TKT in Matrigel@ assays. Matrigel@ is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4'C, but rapidly forms a solid gel at 37 C. Liquid Matrigel@ is mixed 10 with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the TKT. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel@ pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days 15 post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel. In another preferred embodiment, the effect of the candidate modulator on TKT is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, 20 e.g., Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre existing tumor or from in vitro culture. The tumors which express the TKT endogenously are injected in the flank, 1 x 105 to I X 10 7 cells per mouse in a volume of 100 piL using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. 25 Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of 30 diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0. 1M phosphate, pH 7.2, for 6 hours at 4"C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen. 30 WO 2004/067721 PCT/US2004/002321 In another preferred embodiment, tumorogenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, 5 and evaluating the target cells for reaction to the candidate modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator. Tumorogenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can 10 be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc. In another preferred embodiment, a tumorogenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under 15 the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays. In a preferred application, tumor development in the transgenic model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2" transgene, comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell 20 carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812). An "angiogenic switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14 weeks. Candidate modulators may be administered at a variety of stages, including just 25 prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression). Tumorogenicity and modulator efficacy can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc. 30 Diagnostic and therapeutic uses Specific TKT-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the beta-catenin pathway, such as angiogenic, apoptotic, or cell proliferation disorders. 31 WO 2004/067721 PCT/US2004/002321 Accordingly, the invention also provides methods for modulating the beta-catenin pathway in a cell, preferably a cell pre-determined to have defective or impaired beta-catenin function (e.g. due to overexpression, underexpression, or misexpression of beta-catenin, or due to gene mutations), comprising the step of administering an agent to the cell that 5 specifically modulates TKT activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the beta-catenin function is restored. The phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored beta-catenin function, cell proliferation and/or 10 progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for treating disorders or disease associated with impaired beta-catenin function by administering a therapeutically effective amount of a TKT -modulating agent that modulates the beta-catenin pathway. The invention further provides methods for modulating TKT function in a cell, preferably a 15 cell pre-determined to have defective or impaired TKT function, by administering a TKT modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired TKT function by administering a therapeutically effective amount of a TKT -modulating agent. The discovery that TKT is implicated in beta-catenin pathway provides for a 20 variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the beta-catenin pathway and for the identification of subjects having a predisposition to such diseases and disorders. Various expression analysis methods can be used to diagnose whether TKT expression occurs in a particular sample, including Northern blotting, slot blotting, 25 ribonuclease protection, quantitative RT-PCR, and microarray analysis. (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM et al., eds., John Wiley & Sons, Inc., chapter 4; Freeman WM et al., Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective beta-catenin signaling that 30 express a TKT, are identified as amenable to treatment with a TKT modulating agent. In a preferred application, the beta-catenin defective tissue overexpresses a TKT relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial TKT cDNA sequences as probes, can determine whether particular tumors 32 WO 2004/067721 PCT/US2004/002321 express or overexpress TKT. Alternatively, the TaqMan@ is used for quantitative RT PCR analysis of TKT expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems). Various other diagnostic methods may be performed, for example, utilizing 5 reagents such as the TKT oligonucleotides, and antibodies directed against a TKT, as described above for: (1) the detection of the presence of TKT gene mutations, or the detection of either over- or under-expression of TKT mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of TKT gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in 10 the signal transduction pathway mediated by TKT. Kits for detecting expression of NEWGENE in various samples, comprising at least one antibody specific to NEWGENE, all reagents and/or devices suitable for the detection of antibodies, the immobilization of antibodies, and the like, and instructions for using such kits in diagnosis or therapy are also provided. 15 Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in TKT expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for TKT expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or 20 disorder. Preferably, the disease is cancer, most preferably a cancer as shown in TABLE 1. The probe may be either DNA or protein, including an antibody. EXAMPLES The following experimental section and examples are offered by way of illustration 25 and not by way of limitation. I. Drosophila beta-catenin screen Two dominant loss of function screens were carried out in Drosophila to identify genes that interact with the Wg cell signaling molecule, beta -catenin (Riggleman et al. 30 (1990) Cell 63:549-560; Peifer et al. (1991) Development 111:1029-1043). Late stage activation of the pathway in the developing Drosophila eye leads to apoptosis (Freeman and Bienz (2001) EMBO reports 2: 157-162), whereas early stage activation leads to an overgrowth phenotype. We discovered that ectopic expression of the activated protein in the wing results in changes of cell fate into ectopic bristles and wing veins. 33 WO 2004/067721 PCT/US2004/002321 Each transgene was carried in a separate fly stock: Stocks and genotypes were as follows: eye overgrowth transgene: isow; P{3.5 eyeless-Gal4}; P{arm(S56F)-pExp UAS)}/TM6b; 5 eye apoptosis transgene: y w; P{arm(S56F)-pExp-GMR}/CyO; and wing transgene: P{arm(AN)-pExp-VgMQ}/FM7c In the first dominant loss of function screen, females of each of these three transgenes were crossed to a collection of males containing genomic deficiencies. Resulting progeny containing the transgene and the deficiency were then scored for the 10 effect of the deficiency on the eye apoptosis, eye overgrowth, and wing phenotypes, i.e., whether the deficiency enhanced, suppressed, or had no effect on their respective phenotypes. All data was recorded and all modifiers were retested with a repeat of the original cross. Modifying deficiencies of the phenotypes were then prioritized according to how they modified each of the three phenotypes. 15 Transposons contained within the prioritized deficiencies were then screened as described. Females of each of the three transgenes were crossed to a collection of 4 types of transposons (3 piggyBac-based and 1 P-element-based). The resulting progeny containing the transgene and the transposon were scored for the effect of the transposon on their respective phenotypes. All data was recorded and all modifiers were retested with a 20 repeat of the original cross. Modifiers of the phenotypes were identified as either members of the Wg pathway, components of apoptotic related pathways, components of cell cycle related pathways, or cell adhesion related proteins. In the second dominant loss of function screen, females of the eye overgrowth transgene were crossed to males from a collection of 3 types of piggyBac-based 25 transposons. The resulting progeny containing the transgene and the transposon were scored for the effect of the transposon on the eye overgrowth phenotype. All data was recorded and all modifiers were retested with a repeat of the original cross. Modifiers of the phenotypes were identified as either members of the Wg pathway, components of cell cycle related pathways, or cell adhesion related proteins. CG8036 was identified as an 30 enhancer in the screen. BLAST analysis (Altschul et al., supra) was employed to identify orthologs of Drosophila modifiers. For example, representative sequences from TKT, GI#s 4507521, '7110727, and 14149797 (SEQ ID NOs:9, 10, and 11, respectively), share 55%, 46%, and 55% amino acid identity, respectively, with the Drosophila CG8036. 34 WO 2004/067721 PCT/US2004/002321 Various domains, signals, and functional subunits in proteins were analyzed using the PSORT (Nakai K., and Horton P., Trends Biochem Sci, 1999, 24:34-6; Kenta Nakai, Protein sorting signals and prediction of subcellular localization, Adv. Protein Chem. 54, 277-344 (2000)), PFAM (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2), 5 SMART (Ponting CP, et al., SMART: identification and annotation of domains from signaling and extracellular protein sequences. Nucleic Acids Res. 1999 Jan 1;27(1):229 32), TM-HMM (Erik L.L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, 10 T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998), and clust (Remm M, and Sonnhammer E. Classification of transmembrane protein families in the Caenorhabditis elegans genome and identification of human orthologs. Genome Res. 2000 Nov;10(1 1): 1679-89) programs. For example, the transketolase domain (PFAM 00456) of TKT from GI#s 4506521, 7110727, and14149797 15 (SEQ ID NOs:9, 10, and 11, respectively) is located at approximately amino acid residues 14-304, 1-222, and 15-308, respectively. II. High-Throughput In Vitro Fluorescence Polarization Assay Fluorescently-labeled TKT peptide/substrate are added to each well of a 96-well 20 microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of TKT activity. 25 III. High-Throughput In Vitro Binding Assay. 33 P-labeled TKT peptide is added in an assay buffer (100 mM KCI, 20 mM HEPES pH 7.6, 1 mM MgCl 2 , 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite 30 avidin coated assay plate and incubated at 25*C for 1 hour. Biotinylated substrate is then added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS, and counted in a scintillation counter. Test agents that cause a difference in activity relative to control without test agent are identified as candidate beta-catenin modulating agents. 35 WO 2004/067721 PCT/US2004/002321 IV. Immunoprecipitations and Immunoblotting For coprecipitation of transfected proteins, 3 x 106 appropriate recombinant cells containing the TKT proteins are plated on 10-cm dishes and transfected on the following 5 day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors 10 (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at 15,000 x g for 15 min. The cell lysate is incubated with 25 pd of M2 beads (Sigma) for 2 h at 4 'C with gentle rocking. After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel 15 electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech). 20 V. Expression analysis All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues were obtained from Impath, UC Davis, Clontech, Stratagene, Ardais, Genome Collaborative, and Ambion. 25 TaqMan* analysis was used to assess expression levels of the disclosed genes in various samples. RNA was extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/pl. Single stranded cDNA was then synthesized by reverse transcribing the RNA samples using 30 random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA). Primers for expression analysis using TaqMan@ assay (Applied Biosystems, Foster City, CA) were prepared according to the TaqMan@ protocols, and the following criteria: a) primer pairs were designed to span introns to eliminate genomic contamination, 36 WO 2004/067721 PCT/US2004/002321 and b) each primer pair produced only one product. Expression analysis was performed using a 7900HT instrument. TaqMan@ reactions were carried out following manufacturer's protocols, in 25 p.l total volume for 96-well plates and 10 pl total volume for 384-well plates, using 300nM 5 primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis was prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good. The raw data were normalized using 18S rRNA (universally expressed in all tissues and cells). 10 For each expression analysis, tumor tissue samples were compared with matched normal tissues from the same patient. A gene was considered overexpressed in a tumor when the level of expression of the gene was 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue was not available, a universal pool of cDNA samples was used instead. In these cases, a gene was considered 15 overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type was greater than 2 times the standard deviation of all normal samples (i.e., Tumor - average(all normal samples) > 2 x STDEV(all normal samples)). Results are shown in Table 1. Number of pairs of tumor samples and matched 20 normal tissue from the same patient are shown for each tumor type. Percentage of the samples with at least two-fold overexpression for each tumor type is provided. A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with 25 the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other 30 available detection method. 37 WO 2004/067721 PCT/US2004/002321 Table SEQIDNO 7 1 5 Breast 14% 14% 28% # of Pairs 36 36 36 Colon 17% 33% 36% # of Pairs 29 39 39 HeadBAnd-Neck 10% 31% 54% #of Pairs 10 13 13 Kidney 21% 17% 48% # of Pairs 14 23 23 Liver 17% 62% 12% #,of Pairs 6 8 8 Lung 20% 22% 25% #.of Pairs 40 40 40 Lymphoma 75% 75% 0% #.of Pairs 4 4 4 Ovary 16% 32% 32% #of Pairs 19 19 19 Pancreas, 25% 23% 69% # of Pairs - 8 13 13 Prostate 29% 8% 21% # of Pairs 14 24 24 Skin 14% 57% 71% # of Pairsj 7 7 7 Stomach - 18% 45% 45% #4o Pairs ' 11 11 11 Testis 0% 62% 0% # of Pairs 8 8 8 Thyroid Gland 0% 14% 14% # of Pairs 14 14 14 Uterus 18% 52% 35% # of Pairs 22 23 23 VI. TKT functional assays RNAi experiments were carried out to knock down expression of TKTs (SEQ ID 5 NOs:1, 5, and 7) in various cell lines using small interfering RNAs (siRNA, Elbashir et al, supra). Effect of TKT RNAi on cell proliferation and growth. BrdU and Cell Titer-GlOTM assays, as described above, were employed to study the effects of decreased TKT expression on cell proliferation. The results of these experiments indicated that RNAi of 10 SEQ ID NO:1 decreased proliferation in 231T breast cancer cells; RNAi of SEQ ID NO:5 decreased proliferation in 23 IT breast cancer and PC3 prostate cancer cells; and RNAj of SEQ ID NO:7 decreased proliferation in 231T breast cancer, PC3 prostate cancer, and fICT1 16 colon cancer cells. MTS cell proliferation and thymidine incorporation assays, as described above, were also employed to study the effects of decreased TKT expression 38 WO 2004/067721 PCT/US2004/002321 on cell proliferation. The results of this experiment indicated that RNAi of SEQ ID NO: 1 decreased proliferation in PC3 prostate cancer, A549 lung cancer, and RD1 rhabdomyosarcoma cancer cells; RNAi of SEQ ID NO:5 decreased proliferation inPC3, RD1, and A549 cells; and RNAi of SEQ ID NO:7 decreased proliferation in PC3 and 5 A549 cells. Standard colony growth assays, as described above, were employed to study the effects of decreased TKT expression on cell growth. RNAi of SEQ ID NOs: 1, 5, and 7 all caused reduced proliferation in A549 lung cancer, PC3 prostate cancer, HCT 116 and SW480 colon cancer and RD1 rhabdomyosarcoma cancer cells. Effect of TKT RNAi on apoptosis. Nucleosome ELISA apoptosis assay, as 10 described above, was employed to study the effects of decreased TKT expression on apoptosis. RNAi of SEQ ID NOs:1, 5, and 7 caused apoptosis in A549 cells. Effect of TKT RNAi on cell cycle. Propidium iodide (PI) cell cycle assay, as described above, was employed to study the effects of decreased TKT expression on cell cycle. No effects were observed in any of the cell lines studied. The region of subG1 15 represents cells undergoing apoptosis-associated DNA degradation TKT overexpression analysis. TKT (SEQ ID NOs: 1 and 5) were overexpressed and tested in colony growth assays as described above. Overexpressed TKTs had moderate effects on colony number and growth. Further, SEQ ID no: 1 was cotransfected along with Ras into NIH/3T3 cells. The cotransfection resulted in increased colonies in 20 cells cotransfected with RAS and TKT as compared with cells transfected with Ras or TKT alone. TOPFLASH beta-catenin reporter assay. Factors of the TCF/LEF HMG domain family (TCFs) exist in vertebrates, Drosophila melanogaster and Caenorhabditis elegans. Upon Wingless/Wnt signaling, Armadillo/beta-catenin associate with nuclear TCFs and 25 contribute a trans-activation domain to the resulting bipartite transcription factor. So, transcriptional activation of TCF target genes by beta-catenin appears to be a central event in development and cellular transformation. Topflash beta-catenin luciferase gene reporter assay is used as a tool to measures activity of various genes in the beta-catenin pathway by transcriptional activation of TCFs (Korinek, V, et al. (1998) Molecular and Cellular 30 Biology 18: 1248-1256). Briefly, cells are co-transfected with TOPFLASH plasmids containing TCF binding sites driving luciferase, and gene of interest. Transfected cells are then analyzed for luciferase activity. RNAi of SEQ ID NOs: 1 and 5 caused decreased luciferase activity as compared with normal controls. 39 WO 2004/067721 PCT/US2004/002321 High Throughput Beta Catenin Transcriptional readout assay. This assay is an expanded TaqMan* transcriptional readout assay monitoring changes in the mRNA levels of endogenous beta catenin regulated genes. This assay measures changes in expression of beta catenin regulated cellular genes as a readout for pathway signaling activity. 5 We identified a panel of genes that were transcriptionally regulated by beta catenin signaling, then designed and tested TaqMan* primer/probes sets. We reduced expression of beta catenin by RNAi, and tested its affect on the expression of the transcriptionally regulated genes in multiple cell types. The panel readout was then narrowed to the ten most robust probes. 10 We then treated cancer cells with siRNAs of the target genes of interest, such as TKT, and tested how the reduced levels of the target genes affected the expression levels of the beta catenin regulated gene panel. Genes that when knocked out via RNAi, demonstrated the same pattern of activity on at least one panel gene as a beta-catenin knockout, were identified as involved in the 15 beta catenin pathway. TaqMan* assays were performed on the RNAs in a 384 well format. RNAi of SEQ ID NOs: 1 and 5 showed the same pattern of activity as beta catenin RNAi for at least one of the transcriptionally regulated genes. High Throughput active nuclear beta catenin measurement assay. Beta catenin is a 20 cytoplasmic gene, which when activated, moves into the nucleus. This assay was designed to measure the amount of active beta catenin protein in the nucleus using an anti active beta catenin antibody and a nuclear staining dye. Using this assay, we looked for genes that when knocked out, decrease beta catenin activity, and hence, the amount of active beta catenin in the nucleus. This assay was performed using Cellomics Inc. 25 instrumentation. For this assay, cells were transfected in quadruplicate with siRNAs in 96 well format and stained 72 hours post transfection. The amount of nuclear beta catenin was measured using two different methods. RNAi of SEQ ID NOs: I and 5 caused a decrease in the nuclear beta catenin. 30 40

Claims (25)

1. A method of identifying a candidate beta-catenin pathway modulating agent, said method comprising the steps of: 5 (a) providing an assay system comprising a TKT polypeptide or nucleic acid; (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as 10 a candidate beta-catenin pathway modulating agent.

2. The method of Claim 1 wherein the assay system comprises cultured cells that express the TKT polypeptide. 15

3. The method of Claim 2 wherein the cultured cells additionally have defective beta catenin function.

4. The method of Claim 1 wherein the assay system includes a screening assay comprising a TKT polypeptide, and the candidate test agent is a small molecule 20 modulator.

5. The method of Claim 4 wherein the assay is a transferase assay.

6. The method of Claim 1 wherein the assay system is selected from the group consisting 25 of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.

7. The method of Claim 1 wherein the assay system includes a binding assay comprising a TKT polypeptide and the candidate test agent is an antibody. 30

8. The method of Claim 1 wherein the assay system includes an expression assay comprising a TKT nucleic acid and the candidate test agent is a nucleic acid modulator.

9. The method of Claim 8 wherein the nucleic acid modulator is an antisense oligoner. 41 WO 2004/067721 PCT/US2004/002321

10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.

11. The method of Claim 1 additionally comprising: (d) administering the candidate beta-catenin pathway modulating agent identified 5 in (c) to a model system comprising cells defective in beta-catenin function and, detecting a phenotypic change in the model system that indicates that the beta-catenin function is restored.

12. The method of Claim 11 wherein the model system is a mouse model with defective 10 beta-catenin function.

13. A method for modulating a beta-catenin pathway of a cell comprising contacting a cell defective in beta-catenin function with a candidate modulator that specifically binds to a TKT polypeptide, whereby beta-catenin function is restored. 15

14. The method of Claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in beta-catenin function. 20

15. The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

16. The method of Claim 1, comprising the additional steps of: (e) providing a secondary assay system comprising cultured cells or a non-human 25 animal expressing TKT , (f) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and (g) detecting an agent-biased activity of the second assay system, 30 wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate beta-catenin pathway modulating agent, and wherein the second assay detects an agent-biased change in the beta-catenin pathway. 42 WO 2004/067721 PCT/US2004/002321

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-human 5 animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses a beta-catenin pathway gene. 10

20. A method of modulating beta-catenin pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a TKT polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the beta-catenin pathway. 15

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising: 20 (a) obtaining a biological sample from the patient; (b) contacting the sample with a probe for TKT expression; (c) comparing results from step (b) with a control; (d) determining whether step (c) indicates a likelihood of disease. 25

24. The method of Claim 23 wherein said disease is cancer.

25. The method according to Claim 24, wherein said cancer is a cancer as shown in Table 1 as having >25% expression level. 30 43